This is the schedule from the 2018 program. 2020 schedule not yet available.

Thursday, October 18, 2018
6:45am to 7:45am Registration and Breakfast
7:45am to 8:00am Seating
8:00am to 8:15am Welcome and Course Objectives

Samuel Z. Goldhaber, MD and Paul M Ridker, MD


Session Co-Chairs: Paul M Ridker, MD, MPH and Peter Libby, MD

8:15am to 8:35am Atherosclerosis: Biology and Pathophysiology

Peter Libby, MD

8:35am to 8:45am Discussion, Q&A
8:45am to 9:05am Aggressive Lipid Reduction to Minimize Cardiovascular Risk: Focus on PCSK9 Inhibitors

Marc Sabatine, MD, MPH

9:05am to 9:15am Discussion, Q&A
9:15am to 9:55am Anti-inflammatory Therapy to Reduce Risk of Cardiovascular Events and Lung Cancer: CANTOS and Canakinumab

Paul M Ridker, MD, MPH

9:55am to 10:05am Discussion, Q&A
10:05am to 10:25am Reduction of Cardiovascular Events by Decreasing Triglyceride Risk: The PROMINENT Trial

Aruna Pradhan, MD

10:25am to 10:35am Discussion, Q&A
10:35am to 11:05am Combined Antithrombotic and Antiplatelet Therapy to Reduce Cardiovascular Risk: COMPASS Trial, Part I

John Eikelboom, MD

11:05am to 11:15am Discussion, Q&A
11:15am to 11:35am Coffee Break

Refreshments provided

11:35am to 12:05pm Combined Antithrombotic and Antiplatelet Therapy to Reduce Lower Extremity Arterial Disease: COMPASS Trial, Part II

Sonia Anand, MD

12:05pm to 12:15pm Discussion, Q&A
12:15pm to 12:35pm Peripheral Arterial Disease and Thrombotic Risk: Ongoing and Future Trials

Umberto Campia, MD

12:35pm to 12:45pm Discussion, Q&A
12:45pm to 1:05pm Link Between Arterial and Venous Thrombosis

Samuel Z. Goldhaber, MD

1:05pm to 1:15pm Discussion, Q&A
1:15pm to 2:15pm Break for lunch*


Session Co-Chairs: Gregory Piazza, MD, MS and Samuel Z. Goldhaber, MD

2:15pm to 2:45pm Diagnosis of VTE: Clinical Assessment, D-dimer Testing, and Optimal Strategy for Imaging

Henri Bounameaux, MD

2:45pm to 2:55pm Discussion, Q&A
2:55pm to 3:20pm Overview of PE: Epidemiology and Pathophysiology

Samuel Z. Goldhaber, MD

3:20pm to 3:30pm Discussion, Q&A
3:30pm to 3:55pm Anticoagulants for VTE: Focus on DOACs - Ongoing Challenges and Dilemmas

Samuel Z. Goldhaber, MD

3:55pm to 4:05pm Discussion, Q&A
4:05pm to 4:35pm Advanced Therapy: Beyond Anticoagulation

Gregory Piazza, MD, MS

4:35pm to 4:45pm Discussion, Q&A
4:45pm to 5:05pm Inferior Vena Cava Filters: The Good, the Bad, and the Ugly

Henri Bounameaux, MD

5:05pm to 5:15pm Discussion, Q&A
5:15pm to 6:15pm Break


Session Chair: Samuel Z. Goldhaber, MD

6:15pm to 6:30pm Seating
6:30pm to 7:10pm One Brave Idea

Calum MacRae, MD, PhD
The recipient of the American Heart Association’s $75 million One Brave Idea award to understand the earliest stages of coronary heart disease, Dr. MacRae is also also the Vice Chair of Innovation at the Brigham and Women’s Hospital. In addition, Dr. MacRae is a leading investigator at the Brigham and Women’s Hospital Genomics Center, a principal faculty member at the Cardiovascular Research Center and the Harvard Stem Cell Institute, and an associate member at the Broad Institute.

7:20pm to 8:30pm Dinner

Held at Fairmont Copley Plaza

Friday, October 19, 2018
7:00am to 7:45am Breakfast
7:45am to 8:00am Seating


Session Co-Chairs: Samuel Z. Goldhaber, MD and Paul M Ridker, MD, MPH

8:00am to 8:20am DOAC Reversibility: Idaracizumab and Andexanet

Jean Connors, MD

8:20am to 8:30am Discussion, Q&A
8:30am to 8:50am Cancer and VTE: Beyond Low Molecular Weight Heparin Monotherapy

Jean Connors, MD

8:50am to 9:00am Discussion, Q&A
9:00am to 9:20am Heparin-Induced Thrombocytopenia

Jessica Rimsans, PharmD

9:20am to 9:30am Discussion, Q&A
9:30am to 9:50am Adherence to Thrombosis Medications: Problems with Polypharmacy and Promising Solutions

John Fanikos, RPh, MBA

9:50am to 10:00am Discussion, Q&A
10:00am to 10:20am Genetics 2018: What Every Clinician Should Know

Sekar Kathiresan, MD

10:20am to 10:30am Discussion, Q&A
10:30am to 10:50am Coffee break

Refreshments provided


Session Co-Chairs: Deepak L. Bhatt, MD, MPH and Christian T. Ruff, MD, MPH

10:50am to 11:30am KEYNOTE: History of Anticoagulation

Eugene Braunwald, MD
For more than 30 years, Dr. Braunwald has served as Chairman of the TIMI Study Group. Science Watch listed Dr. Braunwald as the most frequently cited author in cardiology; the living Nobel Prize winners in medicine voted Dr. Braunwald “the person who has contributed the most to cardiology in recent years.”

11:30am to 11:40am Discussion, Q&A
11:40am to 12:10pm Mortality Reduction and Stroke Prevention in Atrial Fibrillation: Emergence of Biomarkers for Risk Stratification

Christian T. Ruff, MD, MPH

12:10pm to 12:20pm Discussion, Q&A
12:20pm to 12:40pm Single and Dual Antiplatelet Therapy

John Eikelboom, MD

12:40pm to 12:50pm Discussion, Q&A
12:50pm to 1:10pm Is Triple Therapy with Warfarin Dead?

Deepak L. Bhatt, MD, MPH

1:10pm to 1:20pm Discussion, Q&A
1:20pm to 2:30pm Break for lunch*


Session Co-Chairs: Gregory Piazza, MD, MS and Samuel Z. Goldhaber, MD

2:30pm to 3:00pm Reducing Cardiovascular Thrombotic Events with Contemporary Pharmacologic Therapy for Diabetes Mellitus

Deepak L. Bhatt, MD, MPH

3:00pm to 3:10pm Discussion, Q&A
3:10pm to 3:40pm Hypercoagulability Testing: When, Who, and Why

Jean Connors, MD

3:40pm to 3:50pm Discussion, Q&A
3:50pm to 4:20pm VTE: Fertility and Pregnancy

Gregory Piazza, MD, MS

4:20pm to 4:30pm Discussion, Q&A
4:30pm to 5:00pm VTE Prevention: Meeting the Critical Gap in Prophylaxis During the First Month after Hospitalization

Samuel Z. Goldhaber, MD

5:00pm to 5:10pm Discussion, Q&A
5:10pm Closing Remarks and Adjournment

*There are many convenient and varied lunch options within a short walking distance of the course.